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A B S T R A C T
Introduction: Disturbances in onset and resolution of inflammation in chronic obstructive pulmonary disease
(COPD) are incompletely understood. Dietary polyunsaturated fatty acids (PUFAs) can be converted into lipid
mediators here collectively named oxylipins. These include classical eicosanoids, but also pro-resolving med-
iators. A balanced production of pro-inflammatory and pro-resolving oxylipins is of importance for adequate
inflammatory responses and subsequent return to homeostasis.
Objectives: Here we investigated if PUFA metabolism is disturbed in COPD patients.
Methods: Free PUFA and oxylipin levels were measured in induced sputum samples from the Bergen COPD
cohort and COPD exacerbation study using liquid chromatography-mass spectrometry. Additionally, effects of
whole cigarette smoke on PUFA metabolism in air-liquid interface cultures of primary bronchial epithelial cells
were assessed.
Results: Significantly lower levels of free alpha-linolenic acid, linoleic acid and eicosapentaenoic acid (EPA)
were detected in sputum from stable COPD patients compared to controls. During acute exacerbation (AE), levels
of free arachidonic acid and docosapentaenoic acid were higher than in stable COPD patients. Furthermore,
levels of omega-3 EPA- and docosahexaenoic acid-derived oxylipins were lower in sputum from stable COPD
patients compared to controls. Cyclooxygenase-2-converted mediators were mostly increased during AE. In vitro
studies additionally showed that cigarette smoke exposure may also directly contribute to altered epithelial
PUFA metabolism, and indirectly by causing airway epithelial remodelling.
Conclusions: Our findings show significant differences in PUFA metabolism in COPD patients compared to
controls, further changed during AE. Airway epithelial remodelling may contribute to these changes. These
findings provide new insight in impaired inflammatory resolution in COPD.
1. Introduction
Whereas cigarette smoking is considered the primary cause of
Chronic Obstructive Pulmonary Disease (COPD) in the Western world,
only around 20% of smokers develop COPD [1,2]. After smoking ces-
sation, inflammation in the lungs of COPD patients persists [3], in-
dicating that inflammatory resolution is disturbed in the lungs of these
patients. Over the past decades, research has shown that the resolution
phase of inflammation is initiated by pro-resolving mediators that
predominantly originate from precursors derived from our diet, e.g.
polyunsaturated fatty acids (PUFAs) [4]. Dietary PUFAs (omega-3 and
omega-6) are incorporated in the cell membrane and released upon
exposure of the cell to activating/inflammatory triggers. Released
PUFAs are subsequently converted via enzymatic or non-enzymatic
pathways into lipid mediators, here collectively named oxylipins [5].
Oxylipins include all PUFA derived (intermediate-)mediators including
the well-known leukotrienes and prostaglandins, but also the more re-
cently discovered pro-resolving mediators such as resolvins, protectins
and maresins. The end-stage lipid mediators are converted from PUFAs
either directly, or indirectly via a multiple-step conversion into bio-
chemical intermediate lipid mediators before reaching their final state.
Converting enzymes that are involved include cyclooxygenases (COX),
lipoxygenases (LOX) and cytochrome P450 enzymes (CYP). Depending
on the PUFA released and the enzymes involved, the produced lipid
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mediators will become for example a leukotriene or prostaglandin
(generally omega-6 derived) [6], or a pro-resolving protectin, resolvin
or maresin (generally omega-3 derived) [7].
Previous studies have explored associations between dietary intake
of PUFA (omega-3 and/or -6) and COPD outcomes. Study results
showed associations between high omega-6 fatty acid intake and re-
duction in lung function [8]. Furthermore, an inverse correlation with
high dietary intake of omega-3 fatty acids and the risk to develop COPD
was found [9,10]. No correlation was found between fatty acid intake
and COPD mortality [11]. In line with these findings, disturbances in
fatty acid composition in (erythrocyte) membranes of COPD patients
have been reported [12,13]. However, none of these studies were de-
signed to address causal relationships, and direct investigations on
dietary fatty acid metabolism in the lungs of COPD patients are limited.
Studying PUFA metabolism in COPD might help to understand the
impaired resolution of inflammation in the lungs of patients with COPD
and identify possible therapeutic targets to promote resolution of in-
flammation [14].
This study investigates PUFA metabolism in sputum from patients
with stable COPD in comparison to smoking controls, and changes
herein during acute exacerbations in COPD patients. In addition, al-
terations in PUFA metabolism were investigated in primary air-liquid
interface differentiated bronchial epithelial cell cultures to study direct
effects of whole cigarette smoke exposure on PUFA metabolism.
2. Methods
2.1. Study population and sample selection
Induced sputum samples were collected from participants of the
Bergen COPD Cohort and COPD Exacerbation studies; information on
study design and inclusion criteria was previously published [15–17].
Induced sputum samples from 27 smoking controls (current smokers
and ex-smokers; CTRL), 38 COPD patients in a stable phase (STBL), and
37 patients during an exacerbation (AE) were available for the lipid
analyses described in this study. Baseline characteristics of included
subjects are depicted in Table 1. Controls were age matched to the
COPD population and had samples available at one time-point. Except
for one, no patients received oral steroids at time of sputum sampling.
The full details on sputum induction and processing are previously
published [16]. All data presented in this study are available upon re-
quest from the corresponding author.
2.2. Cell culture
Primary bronchial epithelial cells (PBEC) were obtained from tu-
mour-free resected lung tissue, collected and stored at the Leiden
University Medical Center, Leiden, The Netherlands. PBEC were ex-
panded and cultured at the air-liquid interface (ALI) as described in
[18]. A detailed description is enclosed in the online data supplement.
2.3. Whole cigarette smoke exposure
Methods for exposing the cell cultures to whole cigarette smoke
have been published previously [18]. Detailed information is enclosed
in the online data supplement.
2.4. Liquid chromatography-mass spectrometry sample preparation of
induced sputum samples and primary bronchial epithelial cells
Detailed methods regarding sample preparation of induced sputum
samples and of primary bronchial epithelial cells are enclosed in the
online data supplement.
2.5. Liquid chromatography-mass spectrometry analysis
PUFA-derived lipid mediators in induced sputum and primary
bronchial epithelial cells were measured using RPLC-MS/MS on a
Shimadzu LC-system (Shimadzu's-Hertogenbosch, The Netherlands)
coupled to a QTrap 6500 (ABSciex, Nieuwerkerk a/d IJssel, The
Netherlands). A list of all measured compounds is depicted in
Supplementary Table 1 in the online data supplement. Substances were
identified according to published protocols and class specific internal
standards were used to correct for matrix effects and analyte quantifi-
cation [19,20]. The full method is described elsewhere [21] and any
modifications made in the online data supplement.
Table 1
Baseline characteristics of the included subjects.
Controls Stable COPD pa COPD-AE
n % n % n %
Sex 0.98
Women 12 44.4 17 44.7 15 40.5
Men 15 55.6 21 55.3 22 59.5
Body compositionb 0.48
Normal 23 85.2 28 73.7 26 70.3
Cachectic 1 3.7 4 10.5 5 13.5
Obese 3 11.1 6 15.8 6 16.2
Smoking status 0.001
Never-smoker 2 7.4 – – – –
Ex-smoker 3 11 21 55.3 20 54.0
Current-smoker 22 81.5 17 44.7 17 56.0
Charlson Indexc < 0.001
0 20 74.1 – – – –
1 5 18.5 27 71.1 26 70.3
2 2 7.4 8 21.1 8 21.6
3 – 2 5.3 2 5.4
4 – 1 2.6 1 2.7
GOLD stage
II – 19 51.2 19 50.0
III – 14 37.8 15 39.5
IV – 4 10.8 4 10.5
Using inhaled steroids? < 0.001
No 27 100 9 23.7 8 21.6
Yes – – 29 76.3 29 78.38
Using LTOT?
No 27 100 38 100 37 100
Yes – – – – – –
Continuous variables Controls Stable COPD pa COPD-AE
Mean SD Mean SD Mean SD
Age 0.28
Years 59.2 5.9 60.8 5.9 61.2 5.9
Smoking load 0.22




97.6 8.6 46.2 12.8 < 0.001 45.6 12.9




105.9 9.9 49.8 14.8 < 0.001 49.4 14.6
FVC (% predicted) 106.0 10.0 87.3 13.1 < 0.001 86.6 12.4
Arterial blood gases
pH 7.41 0.021 7.41 0.016 0.10 7.41 0.016
pCO2 (kPa) 5.27 0.39 5.29 0.43 0.85 5.30 0.42
36 COPD patients are paired (have both stable and exacerbation sample).
a Comparing healthy controls to stable COPD.
b Body composition based on bioelectrical impedance measurements of fat
free mass and fat mass.
c All COPD patients will have Charlson 1+ “by default” as COPD=1
Charlson score point.
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2.6. RNA isolation, cDNA synthesis and qPCR
Methods regarding RNA isolation, cDNA synthesis and qPCR ana-
lysis are described in the online data supplement.
2.7. Protein concentrations
Detailed information regarding measurements of the ALI-PBEC
culture protein concentration is enclosed in the online data supplement.
2.8. Data analysis and statistical analysis
Extracted ion chromatograms of detected analytes were integrated
using Multiquant (version 4.1, Sciex) and corrected for their corre-
sponding internal standard. For a subset of analytes which were com-
mercially available at the time of the study, quantitative analysis was
carried out using external calibration lines as described in the
Supplementary Table 1 in the online data supplement, and in a previous
publication [21]. Next, data were corrected for protein levels (PBEC
samples only) and either area/ratio or concentration when available
was used to depict the data. For the correlation plots, only area/ratios
were used in order to enable comparison of all analytes.
Principal component analysis (PCA) was performed with R statis-
tical environment (http://www.r-project.org/, R versions 3.4.3),
“Rcpm”, “pcaMethods” packages were used. For visualisation of the
data correlation structure, the packages “corrr” and “corrplot” were
used. Additional lipid mediator data that was collected but not high-
lighted in the results section can be found in Fig. S1. Univariate sta-
tistical analysis was conducted using GraphPad Prism 7 (GraphPad
Software Inc., La Jolla, CA, U.S.A.). Data are shown as median with
interquartile range unless stated otherwise. The statistical test(s) used
are specified in the legend of each figure. Data in Figs. 1–4 were cor-
rected for multiple hypothesis testing using the two-stage linear step-up
procedure of Benjamini, Krieger and Yekutieli. A maximum of one
outlier per group was removed based on Grubbs testing (alpha= 0.01)
performed on the complete data set of that group. Despite a substantial
overlap in COPD patients from whom samples were available for both
the stable and exacerbation group, we did not perform a paired statis-
tical analysis. The reason for this was that the time between stable
sputum collection and exacerbation was highly variable between pa-
tients, and the order of sample collection differed: from some patients a
sample in the stable phase was collected before the exacerbation
sample, whereas in others it was obtained after the exacerbation during
which a sample was collected. Significant differences for the parameters
in Table 1 were tested using for Sex and Body composition a chi-square
test, for Smoking, Charlson Index and Inhaled steroids a Fishers exact
test and for all Continuous variables a t-test. Differences were con-
sidered significant at p < 0.05.
3. Results
3.1. Lower levels of free alpha linolenic acid, linoleic acid and
eicosapentaenoic acid in sputum from stable COPD patients compared to
controls
Free PUFA levels were assessed in sputum from smoking controls
and COPD patients in a stable phase or during an acute exacerbation
(AE). Significantly lower sputum levels of omega-3 alpha-linolenic acid
(ALA) and eicosapentaenoic acid (EPA, both in Fig. 1A) and omega-6
linoleic acid (LA, Fig. 1B) were found in stable COPD patients compared
to controls. During exacerbation, slight increases in PUFA levels com-
pared to stable COPD were observed which were significant for omega-
3-derived docosapentaenoic acid (DPA, Fig. 1A) and omega-6-derived
arachidonic acid (AA, Fig. 1B) and adrenic acid (AdA, Fig. 1B).
Fig. 1. Free polyunsaturated fatty acid levels in induced sputum from smoking controls and COPD patients in stable phase and during an exacerbation.
LC-MS analysis was performed on induced sputum collected from smoking controls (CTRL, n= 26–27) and COPD patients in a stable phase (STBL, n= 37–38) and
during an acute exacerbation (AE, n=36–37) to assess free polyunsaturated fatty acid (PUFA) levels. A) Levels of free omega-3 PUFA alpha-linolenic acid (ALA)#,
eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA). B) Free omega-6 PUFA levels of linoleic acid (LA), dihomo-gamma-
linoleic acid (DGLA), arachidonic acid (AA) and adrenic acid (AdA). Data are depicted as median with interquartile range. Statistical significance was tested using a
Kruskal-Wallis one-way analysis of variance test followed by a two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli to correct for multiple
comparisons. *p < 0.05, **p < 0.01, ***p < 0.001 between groups.
#Due to technical limitations the signal obtained for the here applied QqQ settings for ALA might result in an approximate 10% overlap with the signal obtained from
GLA.
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3.2. DHA-, EPA- and AA-derived lipid mediator levels are lower in sputum
from stable COPD patients compared to controls
Next, levels of PUFA-derived lipid mediators were assessed. COPD
patients displayed significantly lower sputum levels of all measured
EPA-derived HEPEs (Fig. 2A), three out of four-measured DHA-derived
HDHAs (Fig. 2B), two out of six measured AA-derived HETEs (Fig. 2C)
and all measured AA-derived LTB4's (Fig. 2D) compared to controls.
Since the sputum supernatants were cell-free, gene expression levels of
the converting enzymes could not be assessed. To still obtain an insight
into the activity of the converting pathways, correlations between all
lipid mediators were calculated. In sputum from smoking controls no
strong correlations were found between PUFA levels and their media-
tors (Fig. 3A). However, in stable COPD patients PUFA levels correlated
strongly to most measured lipid mediators (Fig. 3B), suggesting
enhanced activity of several converting pathways (including non-en-
zymatic) as these correlations were not found in controls. These find-
ings are in concordance with the reduced PUFA levels found in stable
COPD patient's sputum and suggest enhanced PUFA conversion in the
airways of stable COPD patients compared to smoking controls.
3.3. Fatty acid conversion via cyclooxygenase-2 is increased during acute
exacerbation
Next, we compared levels of lipid mediators between sputum col-
lected from COPD patients during an acute exacerbation and during a
stable phase, all three measured prostaglandins were significantly in-
creased during AE compared to sputum from stable COPD patients
(Fig. 4A). In addition, also thromboxane B2 (TxB2), 11-HETE, 9-HODE
(all Fig. 4B) and the peroxisome proliferator-activated receptor
Fig. 2. PUFA-derived lipid mediator levels in induced sputum from smoking controls and COPD patients in a stable phase and during exacerbation.
LC-MS analysis was performed on induced sputum collected from smoking controls (CTRL, n= 26–27) and COPD patients in the stable phase (STBL, n=37–38) and
during acute exacerbation (AE, n= 37) to assess PUFA-derived lipid mediators. Data are depicted as median with interquartile range for A) 5-hydro-
xyeicosapentaenoic acid (5-HEPE), 12-HEPE, 15-HEPE and 18-HEPE, B) 7-hydroxydocosahexaenoic acid (7-HDHA), 10-HDHA and 14(S)-HDHA, C) 5-hydro-
xyeicosatetraenoic acid (5-HETE) and 8-HETE and D) 6-trans-leukotriene B4, 6t,12epi-LTB4, 20-OH-LTB4 and LTB4. Data are depicted as median with interquartile
range. Statistical significance was tested using a Kruskal-Wallis one-way analysis of variance test followed by a two-stage linear step-up procedure of Benjamini,
Krieger and Yekutieli to correct for multiple testing. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 between groups.
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activator 8-HETE [22] (Fig. 2C) were significantly increased during AE.
Lastly, 4-HDHA, 9-HOTRE and 18-HEPE were significantly increased
during AE (Fig. 4C).
Correlations between all lipid mediators during exacerbation are
depicted in Fig. 3C and display several interesting observations: i. PUFA
levels did not correlate highly to related mediators, however, COX-2
converted mediators were strongly correlated to each other during AE;
furthermore, ii. the levels of several mediators were highly correlated to
sputum eosinophil levels. Although sputum eosinophil levels during AE
were higher compared to stable (Fig. S2), the number of patients that
displayed these elevated levels was limited. It is therefore difficult to
assess if the observed correlations are of any biological relevance and
these should first be confirmed in a larger cohort.
3.4. Reduced free polyunsaturated fatty acid levels by cigarette smoke-
exposed air-liquid interface cultured primary bronchial epithelial cells
Data obtained from the sputum samples gave insight into changes in
fatty acid metabolism as a consequence of COPD as these values were
compared to those obtained from smoking controls. To investigate
whether whole cigarette smoke (CS) exposure directly affects PUFA
metabolism of airway epithelial cells, primary bronchial epithelial cells
(PBEC) were differentiated at the air-liquid interface (ALI) and exposed
to whole cigarette smoke (CS). Significantly increased cPLA2 gene ex-
pression was detected at 3 and 24 h after CS exposure (Fig. 5A), in-
dicative of an increased fatty acid release from the cell membrane.
Subsequent LC-MS analysis revealed significantly reduced levels of all
detected free PUFAs 24 h after CS exposure of the ALI-PBEC cultures
(Fig. 5B–F), suggesting an increase in fatty acid conversion.
3.5. Cigarette smoke affects fatty acid metabolism in air-liquid interface
cultures of primary bronchial epithelial cells
Next PUFA converting enzymes and lipid mediator release in these
CS-exposed cell cultures was assessed. ALOX15 (15-LOX) expression
was significantly reduced 24 h after CS exposure (Fig. 6A), whereas
PTGS2 (COX-2) gene expression was increased 3 h after CS exposure
and returned to baseline level 24 h thereafter (Fig. 6A). In line with
reduced 15-LOX gene expression, also 15-LOX-mediated PUFA con-
version was affected since 15-HETE, 17-HDHA, 15-HEPE and 5,15 di-
HETE levels were significantly reduced 24 h after CS exposure (Fig. 6B).
Unexpectedly, COX-2-converted prostaglandin levels remained similar
between AIR and CS, despite increased PTGS2 gene expression levels
(Fig. 6C). This could possibly be explained by the lack of effect of CS
exposure on expression of PTGES (data not shown), the enzyme that is
responsible for the conversion of PGH2 into PGE2 following COX-2
conversion, suggesting that PTGES is rate limiting under these condi-
tions.
Fig. 3. Correlations between a variety of parameters in induced sputum from
smoking controls and COPD patients in a stable phase and during exacerbation.
Correlation plots are used to visualize correlations between individual com-
ponents measured in A) controls (CTRL) or B) COPD patients in a stable phase
(STBL) or C) during an acute exacerbation (AE). Negative correlations are de-
picted in red, and positive correlations in blue. The strength of this correlation
is illustrated by the colour key that depicts the correlation coefficient at the
bottom of the figures. Correlations are further emphasized by the thickness of
the line: a thin line indicates highly correlated, a circle indicates low correla-
tion, empty/white indicates no correlation. All abbreviations depicted in the
plot are explained in Supplementary Table 1 in the online data supplement, the
order of the included parameters is alphabetical. Gender was included in the
calculations as a 0 for women and a 1 for men.
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3.6. Differentiation status of the epithelium might contribute to disturbed
fatty acid metabolism in COPD patients
To investigate if airway epithelial remodelling resulting from pro-
longed CS exposure could affect PUFA metabolism, gene expression
levels of the converting enzymes were assessed in luminal cell or basal
cell enriched fractions of (unexposed) ALI-PBEC cultures in a previously
acquired and validated data set [18]. ALOX15 expression was higher in
the luminal cell-enriched fraction compared to the basal cell-enriched
fraction, while this was vice versa for PTGS2 expression (Fig. 7A). In an
additional existing data set from a study in which we assessed effects of
daily exposure (up to 19 days) on differentiating ALI-PBEC cultures to
whole CS [18], we measured ALOX15 and PTSG2 expression during
differentiation in presence or absence of chronic CS exposure. Data
showed that chronic CS exposure during differentiation resulted in a
markedly decreased expression of ALOX15 as compared to air-exposed
controls where an increase during epithelial differentiation was ob-
served (Fig. 7B). Furthermore, PTGS2 expression was strongly reduced
as a result of epithelial differentiation, but this was not affected by CS
exposure (Fig. 7C). As we previously established that chronic CS ex-
posure results in changes in cellular composition of the airway epi-
thelial cell cultures [18], and now also see changes in PUFA converting
enzymes, these data indicate that CS-induced remodelling of the airway
epithelium may influence the expression of the PUFA-converting en-
zymes favoring the expression of COX-2.
4. Discussion
Traditionally PUFA metabolism has been studied for conversion into
eicosanoids such as leukotrienes and prostaglandins. In recent years
Fig. 4. Changes in lipid mediators during acute exacerbation.
LC-MS analysis was performed on induced sputum from smoking controls (CTRL, n=26–27) and stable COPD patients (STBL I, n= 37–38) and COPD patients
during acute exacerbation (AE, n= 36–37) to assess PUFA-derived lipid mediators. A) Medians with interquartile range are depicted for prostaglandin D2 (PGD2),
prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), for B) thromboxane B2 (TXB2), 11-hydroxyeicosatetraenoic acid (11-HETE) and 9-Hydroxyoctadecadienoic acid
(9-HODE) and C) 4-hydroxydocosahexaenoic acid (4-HDHA), 9-hydroxy-10E,12Z,15Z-octadecatrienoic acid (9-HOTRE) and 18-hydroxyeicosapentaenoic acid (18-
HEPE). Statistical significance was tested using a Kruskal-Wallis one-way analysis of variance test followed by a two-stage linear step-up procedure of Benjamini,
Krieger and Yekutieli to correct for multiple testing. *p < 0.05, ***p < 0.001, ****p < 0.0001 between groups.
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important activities of novel PUFA-derived lipid mediators have been
discovered that promote resolution of inflammation. Such mediators
may be especially important in chronic inflammatory diseases where
resolution of inflammation is lacking. These lipid mediators may impact
disease pathology and could serve as therapeutic targets to increase
resolution of inflammation.
As little is known about PUFA metabolism in COPD, we aimed to
investigate PUFA metabolism in stable COPD patients and during acute
exacerbations and compare with smokers without COPD. We observed
lower levels of several omega-3 and -6 PUFAs in sputum from patients
with stable COPD compared to smoking controls. Both EPA and DHA
are important sources for pro-resolving mediators, and reduced levels of
these PUFAs could therefore limit the availability of these pro-resolving
mediators. Unfortunately, the supernatants of sputum we used were
cell-free and no plasma or erythrocyte samples were available. We
could therefore not assess whether cell membranes in these patients
also showed signs of reduction in levels of PUFAs or whether our
findings are also reflected on a systemic level. This is relevant, since
several studies have reported lower levels of free fatty acids [23] or
PUFAs [24] in plasma and of (specific omega-3) PUFAs in erythrocyte
cell membranes from patients with COPD compared to controls [13].
Malnutrition was suggested to underlie the observed reduced PUFA
levels in one study [23]. However, as our correlation plots from stable
COPD patients suggested a general enhancement of PUFA conversion
compared to controls, the question arises whether reduced levels of
fatty acids solely reflect malnutrition of these patients, or whether en-
hanced PUFA metabolism in COPD may deplete essential fatty acids
also when sufficient amounts are consumed and incorporated into the
cellular membranes. Supplementation with omega-3-derived pro-re-
solving mediators rather than omega-3 fatty acids themselves might
therefore be warranted in COPD patients as a possible strategy to pro-
mote inflammation resolution. Several studies support this therapeutic
strategy as results show beneficial effects of pro-resolving compounds
on cellular function and inflammation in vitro [25] and in mice models
[26–28] using CS or organic dust exposures. A possible explanation for
the alteration in PUFA conversion in COPD was provided by our in vitro
data and those of others [29], suggesting that remodelling of the airway
epithelium could underlie the altered conversion of PUFAs in patients
with COPD. Remodelling was found to markedly impact the expression
of the converting enzymes and possibly also their activity, although the
latter has yet to be proven. Since epithelial remodelling is more pro-
nounced in COPD patients than in (ex)smoking controls with a normal
lung function, our in vitro studies help to explain the observed differ-
ences in sputum lipid mediator levels between COPD patients and
Fig. 5. Whole cigarette smoke exposure of
air-liquid interface cultured primary bron-
chial epithelial cells promotes cPLA2 gene
expression and reduces free poly-
unsaturated fatty acid levels.
Primary bronchial epithelial cells (PBEC),
cultured at the air-liquid interface (ALI)
were exposed to whole cigarette smoke, at
3 h and 24 h thereafter, gene expression of
cPLA2 was assessed (A), or cultures were
harvested for LC-MS analysis to determine
levels of linoleic acid (LA), alpha-linolenic
acid and gamma linoleic acid (ALA/GLA)#,
arachidonic acid (AA), eicosapentaenoic
acid (EPA), and docosahexaenoic acid
(DHA) (B–F). Data are depicted as median
with interquartile range. Data in A are
shown as target gene expression normalized
for the geometric mean expression of the
reference genes ATP synthase, H+ trans-
porting, mitochondrial F1 complex, beta
polypeptide (ATP5B) and Ribosomal
Protein L13a (RPL13A); n= 21 different
donors. Statistical significance between
groups was tested using a non-parametric
one-way ANOVA Friedman test with a
Dunn's multiple comparisons post hoc test.
*p < 0.05, **p < 0.01, ***p < 0.001.
#Due to technical limitations the signal
obtained for the here applied QqQ settings
(ALA/GLA) shown in panel C accounts for
measurement of both ALA and GLA.
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controls. Additional research is needed to determine the feasibility of a
therapeutic strategy targeting this pathway to promote resolution in the
lungs of patients with COPD. This is supported by a study in mice,
showing beneficial effects of Resolvin D1 on lung inflammation caused
by cigarette smoke exposure [28].
This study has several limitations that are worth mentioning: i. no
conclusions can be drawn regarding the role of PUFA metabolism in
COPD disease severity and progression, since stratification on GOLD
stage was not possible because of the small patient numbers in this
study, ii. Standardization of sample collection: samples from COPD
patients in STBL and AE phases were mostly paired (same donor for
both situations), however as these were collected at very different time
points between patients and in different order of sampling, paired
testing could not be performed; furthermore no long-term follow up
samples were available. iii. No end products such as resolvins or mar-
esins could be detected in the sputum samples, however many pre-
cursors could be found. One reason for this could be a possible short in
vivo half-life of these end-products [30,31], or possible binding of these
compounds to receptors on cell membranes (e.g. for signalling pur-
poses) [32]. Lastly, no dietary information is available of these donors
Fig. 6. Whole cigarette smoke exposure of
air-liquid interface cultured primary bron-
chial epithelial cells reduces ALOX15 (15-
LOX) expression and converted mediators.
Primary bronchial epithelial cells (PBEC),
cultured at the air-liquid interface (ALI)
were exposed to whole cigarette smoke
(CS), at 3 h and 24 h thereafter, gene ex-
pression of ALOX15 (15-LOX, A) and PTGS2
(COX-2, B) was assessed. In addition, cul-
tures were harvested for LC-MS analysis to
determine levels of 5,15-dihydrox-




acid (17-HDHA), prostaglandin E2 (PGE2)
and prostaglandin F2α (PGF2α) (C–F). Data
are depicted as median with interquartile
range. Data in A and B are shown as target
gene expression normalized for the geo-
metric mean expression of the reference
genes ATP synthase, H+ transporting, mi-
tochondrial F1 complex, beta polypeptide
(ATP5B) and Ribosomal Protein L13a
(RPL13A); n= 21 different donors.
Statistical significance between groups was
tested using a non-parametric one-way
ANOVA Friedman test with a Dunn's mul-
tiple comparisons post hoc test. **p < 0.01,
***p < 0.001, ****p < 0.0001.
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during the time of the study and we therefore cannot discriminate if the
observed findings were partly a result of changes in diet in this patient
group, an intrinsic change in the metabolism, or both. Despite these
limitations, the results show clear differences between groups, further
supported by unsupervised multivariate analysis. A score plot of a
principal component analysis (PCA) model (Fig. S3) illustrates a degree
of the groups clustering; with the first two components covering> 50%
of the total variance trend for the group relate clustering is evident. Off
note, only one COPD patient used oral steroids at time of sputum
sampling, and therefore this is unlikely to have affected the data.
It is interesting to note that during AE, the pattern of produced lipid
mediators was strongly skewed in presence of high sputum eosinophil
numbers. In contrast to neutrophils, eosinophils express the 15-LOX
converting enzyme [33] and we indeed found that high eosinophil le-
vels strongly correlated with the presence of 15-LOX-converted med-
iators. In addition, high sputum eosinophil levels correlated with high
LTE4 levels, an eicosanoid produced by eosinophils. LTE4 is a known
bronchoconstrictor [34], that also activates Th2 cells, induces IL-8 gene
expression by Th2 cells and promotes neutrophil activation (e.g. mi-
gration and survival) in vitro [35]. As not all, but only a small subgroup
of patients displayed high sputum eosinophil levels (Fig. S2), it is
tempting to speculate that patients with high levels of eosinophils and
the correlated mediators represent a specific subgroup of COPD patients
such as for example ACOS patients (Asthma COPD Overlap Syndrome)
who are characterized by Th2 inflammation, including increased levels
of eosinophils. Our observations suggest a molecular basis for the use of
cysteinyl-leukotriene receptor (CysLT) antagonists such as montelukast
in COPD, which have shown possible beneficial effects on the ther-
apeutic control of COPD [36]. Possibly COPD subgroups with high LTE4
levels during AE may benefit from a personalized therapeutic approach
using Cys-LT receptor antagonists and/or COX-2 inhibitors.
During AE, we furthermore noticed increased levels of COX-2-con-
verted prostaglandins and thromboxane B2 that showed a negative
correlation with FEV1, particularly in the case of PGE2 and PGF2α. An
inverse correlation between PGE2 and FEV1 in induced sputum from
COPD patients was also reported by others [37,38] and suggested to be
mediated by MMP-2 [37]. Our in vitro data show how both acute ci-
garette smoke exposure and remodelling of the airway epithelium as a
result of this exposure could favour expression of COX-2 at a cost of
expression of LOX enzymes, therefore we hypothesize that the pro-
duction of prostaglandins could also be related to the level of epithelial
remodelling. Unexpectedly, in contrast to the previously mentioned
study [38], we did not find increased LTB4 levels in sputum from
patients with COPD, rather a reduction. This could be explained by the
fact that our controls are smoking controls and possibly these already
have elevated levels in their sputum. It could also be a discrepancy
between exhaled breath condensate used in the referred study and
sputum in our study as this has been shown to not give similar results
with regard to LTB4 levels [39].
In summary, we show that patients with COPD have disturbed PUFA
metabolism in stable state and during AE with indications of compro-
mised production of precursors for pro-resolving mediators. We fur-
thermore show in vitro that both acute exposure of the airway epithe-
lium as well as smoke-induced remodelling of the airway epithelium
could contribute to changes in PUFA metabolism.
Further investigations are needed to understand how changes in
PUFA conversion and derived lipid mediator levels modulate airway
epithelial functioning and differentiation. This knowledge is essential to
delineate the potential of PUFA metabolism as therapeutic target to
promote resolution of chronic lung inflammation in COPD patients.
Furthermore, our findings propose that molecular investigations such as
those in the presented study may contribute to the development of
personalized therapies for specific groups of COPD patients.
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